A2A adenosine receptor stimulation ameliorated diabetic-induced osteoporosis in rats.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-07-01 DOI:10.4149/gpb_2024018

Manal S Abd-El Hamid, Ebtessam A Abou-Shady, Nourhan A Mohamed, Wessam E Morsy

{"title":"A2A adenosine receptor stimulation ameliorated diabetic-induced osteoporosis in rats.","authors":"Manal S Abd-El Hamid, Ebtessam A Abou-Shady, Nourhan A Mohamed, Wessam E Morsy","doi":"10.4149/gpb_2024018","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic osteoporosis is a common health problem that is associated with a disruption in bone metabolism. A2A adenosine receptor (A2AAR) signaling seems to play a critical role in bone homeostasis. This study aimed to evaluate the effect of A2AAR stimulation on the treatment of diabetic-induced osteoporosis versus insulin treatment. Forty adult male rats were allocated into control (C), untreated diabetic-induced osteoporosis (DIO), insulin-treated DIO (I-DIO), and A2AAR agonist-treated DIO (A-DIO) groups. Both insulin and A2AAR agonist treatments significantly increased serum insulin level, glutathione peroxidase (GPx) activity, bone expression of osteoprotegerin (Opg) and β-catenin (Ctnnb1), and cortical and trabecular bone thickness, whereas they decreased serum fasting glucose, malondialdehyde (MDA), tumor necrosis factor α (TNF-α), bone expression of receptor activator of nuclear factor kappa-B ligand (Rankl), runt-related transcription factor-2 (Runx2), and sclerostin (Sost) versus the untreated DIO groups. A2AAR agonist treatment was more effective than insulin in ameliorating diabetic osteoporosis. This might be attributed to the upregulation of β-catenin gene expression, enhancing its anabolic effect on bone, in addition to the A2AAR agonist's anti-oxidative, anti-inflammatory, and anti-diabetic effects.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.4149/gpb_2024018","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetic osteoporosis is a common health problem that is associated with a disruption in bone metabolism. A2A adenosine receptor (A2AAR) signaling seems to play a critical role in bone homeostasis. This study aimed to evaluate the effect of A2AAR stimulation on the treatment of diabetic-induced osteoporosis versus insulin treatment. Forty adult male rats were allocated into control (C), untreated diabetic-induced osteoporosis (DIO), insulin-treated DIO (I-DIO), and A2AAR agonist-treated DIO (A-DIO) groups. Both insulin and A2AAR agonist treatments significantly increased serum insulin level, glutathione peroxidase (GPx) activity, bone expression of osteoprotegerin (Opg) and β-catenin (Ctnnb1), and cortical and trabecular bone thickness, whereas they decreased serum fasting glucose, malondialdehyde (MDA), tumor necrosis factor α (TNF-α), bone expression of receptor activator of nuclear factor kappa-B ligand (Rankl), runt-related transcription factor-2 (Runx2), and sclerostin (Sost) versus the untreated DIO groups. A2AAR agonist treatment was more effective than insulin in ameliorating diabetic osteoporosis. This might be attributed to the upregulation of β-catenin gene expression, enhancing its anabolic effect on bone, in addition to the A2AAR agonist's anti-oxidative, anti-inflammatory, and anti-diabetic effects.

查看原文本刊更多论文

A2A 腺苷受体刺激可改善糖尿病诱发的大鼠骨质疏松症。

糖尿病骨质疏松症是一种常见的健康问题，与骨代谢紊乱有关。A2A腺苷受体（A2AAR）信号似乎在骨平衡中发挥着关键作用。本研究旨在评估刺激 A2AAR 与胰岛素治疗相比对糖尿病诱导的骨质疏松症的治疗效果。40 只成年雄性大鼠被分为对照组（C）、未治疗糖尿病诱导的骨质疏松症组（DIO）、胰岛素治疗的骨质疏松症组（I-DIO）和 A2AAR 激动剂治疗的骨质疏松症组（A-DIO）。胰岛素和 A2AAR 激动剂治疗均能显著提高血清胰岛素水平、谷胱甘肽过氧化物酶（GPx）活性、骨保护蛋白（Opg）和β-catenin（Ctnnb1）的骨表达以及皮质和骨小梁厚度，同时降低血清空腹血糖、与未经治疗的 DIO 组相比，它们能降低血清空腹血糖、丙二醛 (MDA)、肿瘤坏死因子 α (TNF-α)、核因子卡巴-B 配体受体激活剂 (Rankl)、runt 相关转录因子-2 (Runx2) 和硬骨素 (Sost) 的骨表达。在改善糖尿病骨质疏松症方面，A2AAR 激动剂治疗比胰岛素治疗更有效。除了 A2AAR 激动剂的抗氧化、抗炎和抗糖尿病作用外，这可能是由于上调了 β-catenin 基因的表达，增强了其对骨骼的同化作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.